Cyteir Therapeutics, Inc.
RAD51 inhibitor small molecule therapeutics targeting AID-positive B-cell lymphomas and leukemias
- Sector
- Biotech
- Headquarters
- LEXINGTON, MA
- Founded
- 2012
- Latest Form D
- $80M, Feb 2021
- Total capital
- $115M
- Federal grants
- $4M
- 3 awards · 2016–2017
- Rank in peer group#237 of 514
- Private capital raised
- $111M
- 4 Form D · last Feb 2021
- 68 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 8
- 32 pending · first 2019
- Rank in peer group#40 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$80M
- Private capital raisedForm D · SEC · 3rd filing$20.2M
- Private capital raisedForm D · SEC · 2nd filing$4.8M
- Federal grantHealth and Human S · Phase II · Developing Therapeutics That Target RAD51 To Treat Leukemia and Lymphoma$961K
- Federal grantHealth and Human S · Phase II · Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma$2M
- Federal grantHealth and Human S · Phase II · Developing Therapeutics That Target RAD51 To Treat Leukemia and Lymphoma$1M
- Private capital raisedForm D · SEC · 1st filing$5.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#237 · top 46%
- Granted patents#40 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Kevin MillsResearcherExecutive Officer, DirectorLinked by $4M in grants as PI
- ANDREW S. GENGOSExecutive OfficerNamed in SEC Form D filings
- Barry B. MillsDirectorNamed in SEC Form D filings
- Bart Van HoolandDirectorNamed in SEC Form D filings
- Donald CorcoranExecutive Officer, DirectorNamed in SEC Form D filings
- JANWILLEM NAESENSDirectorNamed in SEC Form D filings
Show all 16 people
- Jean GeorgeDirectorNamed in SEC Form D filings
- JOSEPH S. ZAKRZEWSKIDirectorNamed in SEC Form D filings
- KAREN HONGDirectorNamed in SEC Form D filings
- MARKUS RENSCHLERExecutive Officer, DirectorNamed in SEC Form D filings
- PAUL S. SECRISTExecutive OfficerNamed in SEC Form D filings
- Racquel BrackenDirectorNamed in SEC Form D filings
- Ronald GoldsteinExecutive OfficerNamed in SEC Form D filings
- SUSAN S. MOLINEAUXDirectorNamed in SEC Form D filings
- Timothy RombergerExecutive Officer, DirectorNamed in SEC Form D filings
- William B. Asher, Jr.Executive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 40- Pending4-AMINOPHENYL-THIAZOLE Derivatives And Methods Of Use ThereofUSPTOApplication 18859622
- PendingMethods Of Using A (thiazolyl)benzenesulfonamide DerivativeUSPTOApplication 18859639
- PendingMethods Of Using A (thiazolyl)benzenesulfonamide DerivativeUSPTOApplication 18859616
Show all 40 patent records
- 4-AMINOPHENYL-THIAZOLE Derivatives And Methods Of Use ThereofSep 4, 2025 · Application 18859622Pending
- Methods Of Using A (thiazolyl)benzenesulfonamide DerivativeAug 28, 2025 · Application 18859639Pending
- Methods Of Using A (thiazolyl)benzenesulfonamide DerivativeJun 12, 2025 · Application 18859616Pending
- RAD51 InhibitorsMay 1, 2025 · Application 18818708Pending
- Methods Of Using RAD51 Inhibitors For Treatment Of Pancreatic CancerMar 13, 2025 · Application 18766813Pending
- Method For Preparing Cyclohexyl Thiazolyl Phenyl CarbamateFeb 13, 2025 · Application 18798938Pending
- RAD51 InhibitorsOct 31, 2024 · Application 18427164Pending
- Methods Of Using RAD51 Inhibitors For Treatment Of Pancreatic CancerAug 20, 2024 · US 12,064,419Granted
- RAD51 InhibitorsMar 19, 2024 · US 11,932,636Granted
- Combinations Of RAD51 And Parp InhibitorsMar 21, 2023 · US 11,607,404Granted
- RAD51 InhibitorsApr 5, 2022 · US 11,291,655Granted
- RAD51 InhibitorsFeb 24, 2022 · Application 17363099Pending
- RAD51 InhibitorsFeb 15, 2022 · US 11,247,988Granted
- Targeting Homologous Recombination For Treating CancerSep 9, 2021 · Application 17191220Pending
- RAD51 InhibitorsAug 10, 2021 · US 11,084,812Granted
- RAD51 InhibitorsMar 17, 2020 · US 10,590,122Granted
- RAD51 InhibitorsJul 2, 2019 · US 10,336,746Granted
- Methods Of Using A (thiazolyl)benzenesulfonamide DerivativeApplication 63417666Pending
- Methods Of Using A (thiazolyl)benzenesulfonamide DerivativeApplication 63417647Pending
- Methods Of Using A (thiazolyl)benzenesulfonamide DerivativeApplication 63358325Pending
- Methods Of Using A (thiazolyl)benzenesulfonamide DerivativeApplication 63334575Pending
- Methods Of Using A (thiazolyl)benzenesulfonamide DerivativeApplication 63334591Pending
- 4-AMINOPHENYL-THIAZOLE Derivatives And Methods Of Use ThereofApplication 63334589Pending
- Targeting Homologous Recombination: A New Sythetic Lethal Therapeutic ParadigmApplication PCTUS2021020661Pending
- Targeting Homologous Recombination: A New Synthetic Lethal Therapeutic ParadigmApplication 63148683Pending
- Methods Of Using RAD51 Inhibitors For Treatment Of Pancreatic CancerApplication PCTUS2020038895Pending
- Combinations Of RAD51 And Parp InhibitorsApplication PCTUS2020024601Pending
- RAD51 InhibitorsApplication PCTUS2020022293Pending
- Targeting Homologous Recombination: A New Synthetic Lethal Therapeutic ParadigmApplication 62984765Pending
- Methods Of Using RAD51 Inhibitors For Treatment Of Pancreatic CancerApplication 62895138Pending
- Methods Of Using RAD51 Inhibitors For Treatment Of Pancreatic CancerApplication 62864861Pending
- Combinations Of RAD51 And Parp InhibitorsApplication 62823556Pending
- RAD51 InhibitorsApplication 62816998Pending
- RAD51 InhibitorsApplication PCTUS2018050391Pending
- RAD51 InhibitorsApplication 62711959Pending
- Solid Forms Of Cyclohexyl Thiazolyl Phenyl Carbamate And Methods Of Use ThereofApplication PCTUS2024061374Pending
- RAD51 InhibitorsApplication PCTUS2018041588Pending
- Method For Preparing Cyclohexyl Thiazolyl Phenyl CarbamateApplication PCTUS2024041800Pending
- 3,4-FUSED Bicyclic Pyrrolidine And 3,4-FUSED Bicyclic Pyrrolidinone CompoundsApplication PCTUS2024019513Pending
- Substituted Pyrrolidine And Pyrrolidinone CompoundsApplication PCTUS2024017466Pending
Related companies, and why
- Calder Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- CRIMSON BIOPHARM INCSimilar federal contract value in Biotech · null in contracts
- TOSK, INC.Similar federal contract value in Biotech · null in contracts
- AYANA BIO LLCSimilar federal contract value in Biotech · null in contracts
- PRIMAL THERAPIES, INC.Similar federal contract value in Biotech · null in contracts
- Novoglia, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .